The health regulator set out conditions to lift a suspension of Johnson & Johnson’s COVID-19 vaccine.
South Africa’s health regulator has recommended that the government lift the suspension of COVID-19 vaccine administration by pharmaceutical manufacturer Johnson & Johnson, provided certain conditions are met.
“These conditions include, but are not limited to, enhanced screening and monitoring of participants at high risk of coagulation disorder,” South African Health Products Authority (SAHPRA). said Saturday.
“Additionally, measures will be taken to ensure the safe management of any participant who develops vaccine-induced thrombocytopenia and thrombocytopenia (VITT),” the statement added.
SAHPRA said that it recently looked at data from a local Johnson & Johnson study on vaccination of health workers and found no significant safety concerns.
South Africa suspended the implementation of J&J vaccines in the “development study” on Tuesday, after health authorities in the United States recommended suspending the use of the vaccine because of rare cases. met blood clots in six vaccinated people, out of about seven million people who received shot in the water.
A US panel will meet again next week to discuss whether the suspension of vaccine use should continue after delaying a vote on the matter earlier this week.